Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT.

View Full Paper
Ask AI
Bookmark
Share

Authors

KRKara‐Louise RoyleBDBryony DawkinsBKBhuvan Kishore

Discussion

Loading...

Member takes

Overview

Randomised trial found frailty-score adapted therapy improves outcomes in UNFIT myeloma patients, indicating risks for FRAIL patients.

Key Points

  • To assess the impact of frailty-score adjusted dosing on toxicity and outcomes in frail myeloma patients.
  • Phase III randomised controlled trial
  • Comparison of standard and adjusted dosing therapies
  • Assessment of frail and unfit patient outcomes
  • No significant difference in early treatment cessation between dosing strategies for all patients
  • Frail patients exhibited inferior outcomes and did not benefit from adjusted dosing
  • UNFIT patients showed improved outcomes with frailty-score adjusted dosing

Cite This Study

Royle et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e094https://doi.org/10.1182/blood-2025-369
View Full Paper
Ask AI
Bookmark
Share